![Bayer AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png?tr=w-200)
Bayer AG
XETRA:BAYN
![Bayer AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.35
53.14
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png)
Intrinsic Value
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. [ Read More ]
The intrinsic value of one
BAYN
stock under the Base Case scenario is
114.934
EUR.
Compared to the current market price of 27.465 EUR,
Bayer AG
is
Undervalued by 76%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png?tr=w-200)
Valuation Backtest
Bayer AG
Run backtest to discover the historical profit from buying and selling
BAYN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bayer's Mixed Q1 2024 Earnings with Strategic Focus
Earnings Call Summary
Bayer's Q1 2024 earnings showed mixed results. Sales were slightly down at EUR 13.8 billion, and core earnings per share dropped to EUR 2.82. However, free cash flow improved significantly to minus EUR 2.6 billion due to lower litigation payouts. Crop Science outperformed in a tough market, despite a 3% sales decline due to lower glyphosate prices. Pharmaceuticals saw a 4% sales growth driven by Nubeqa, Kerendia, and Eylea. Consumer Health faced a 2% sales drop but is confident in H2 growth with new product launches like Iberogast. Bayer reaffirms its 2024 guidance, targeting 3-6% CPA growth and 23-24% EBITDA margin.
Balance Sheet Decomposition
Bayer AG
Current Assets | 40.2B |
Cash & Short-Term Investments | 8.9B |
Receivables | 17.8B |
Other Current Assets | 13.5B |
Non-Current Assets | 79.7B |
Long-Term Investments | 3.2B |
PP&E | 13.5B |
Intangibles | 56.1B |
Other Non-Current Assets | 6.9B |
Current Liabilities | 30.6B |
Accounts Payable | 6.4B |
Other Current Liabilities | 24.2B |
Non-Current Liabilities | 53.6B |
Long-Term Debt | 38B |
Other Non-Current Liabilities | 15.7B |
Earnings Waterfall
Bayer AG
Revenue
|
47B
EUR
|
Cost of Revenue
|
-19.5B
EUR
|
Gross Profit
|
27.5B
EUR
|
Operating Expenses
|
-26.8B
EUR
|
Operating Income
|
731m
EUR
|
Other Expenses
|
-3.9B
EUR
|
Net Income
|
-3.1B
EUR
|
Free Cash Flow Analysis
Bayer AG
EUR | |
Free Cash Flow | EUR |
BAYN Profitability Score
Profitability Due Diligence
Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png)
Score
Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
BAYN Solvency Score
Solvency Due Diligence
Bayer AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png)
Score
Bayer AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAYN Price Targets Summary
Bayer AG
According to Wall Street analysts, the average 1-year price target for
BAYN
is 34.448 EUR
with a low forecast of 25.25 EUR and a high forecast of 64.05 EUR.
Price Appreciation
BAYN Price
Bayer AG
Average Annual Return | 0.43% |
Standard Deviation of Annual Returns | 22.47% |
Max Drawdown | -62% |
Market Capitalization | 27B EUR |
Shares Outstanding | 982 424 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
![Bayer AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png?tr=w-200)
![Bayer AG Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/bayn.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
Contact
IPO
Employees
Officers
The intrinsic value of one
BAYN
stock under the Base Case scenario is
114.934
EUR.
Compared to the current market price of 27.465 EUR,
Bayer AG
is
Undervalued by 76%.